Vitamin Shoppe recommended ahead of Q2 report at Goldman Goldman believes Vitamin Shoppe (VSI) competitive pressures are overblown and that the company has relatively low overlap with GNC (GNC) and that recent price cuts have had minimal impact. The firm expects Vitamin Shoppe's Q2 to mark the beginning of sharp earnings acceleration and better execution and recommends buying shares ahead of the Q2 report. Shares are rated Conviction Buy with a $60 price target.
Vitamin Shoppe downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray downgraded Vitamin Shoppe to Neutral after its study indicated the company's prices remain elevated versus the competition. Piper believes Vitamin Shoppe may have to invest in price and lowered its price target for shares to $44 from $45.